| 產品名稱 |
NCI-BL2028 [BL2028] |
| 商品貨號 |
B165238 |
| Organism |
Homo sapiens, human |
| Tissue |
peripheral blood |
| Cell Type |
B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Carcinoma |
| Age |
72 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Derivation |
NCI-BL2028BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a patient with metastatic small cell lung carcinoma. |
| Clinical Data |
NCI-BL2028BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a patient with metastatic small cell lung carcinoma. male Caucasian 72 years |
| Comments |
NCI-BL2028BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a patient with metastatic small cell lung carcinoma. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp6 viable cells/ml. Maintain cell density between 1 X 10 exp6 and 3 X 10 exp6 viable cells/ml. |
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| Name of Depositor |
AF Gazdar, JD Minna |
| Deposited As |
Homo sapiens |
| References |
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|
